| P50 | author | Jessica Zucman-Rossi | Q43376269 |
| P2093 | author name string | Kornelius Schulze | |
| P2860 | cites work | Molecular-based prediction of early recurrence in hepatocellular carcinoma | Q80406680 |
| | Molecular prediction of early recurrence after resection of hepatocellular carcinoma | Q83234955 |
| | Clinical significance and prognostic value of microRNA expression signatures in hepatocellular carcinoma | Q87021317 |
| | Genetics of hepatocellular carcinoma: the next generation | Q87341065 |
| | Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. | Q26782024 |
| | Mutational signatures: the patterns of somatic mutations hidden in cancer genomes | Q26850125 |
| | Unique genomic profile of fibrolamellar hepatocellular carcinoma | Q27853116 |
| | Management of hepatocellular carcinoma: An update | Q27860530 |
| | EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma | Q27860783 |
| | Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 |
| | Significance of CD90+ cancer stem cells in human liver cancer | Q28266933 |
| | Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators | Q28267500 |
| | Deciphering signatures of mutational processes operative in human cancer | Q28283300 |
| | Hepatocellular carcinoma: epidemiology and molecular carcinogenesis | Q28306363 |
| | Signatures of mutational processes in human cancer | Q29547191 |
| | Hepatocellular carcinoma | Q29615765 |
| | Management of hepatocellular carcinoma | Q29616230 |
| | Hepatocellular carcinoma | Q29616359 |
| | Intra-tumour heterogeneity: a looking glass for cancer? | Q29620149 |
| | Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma | Q30479629 |
| | EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features | Q30493364 |
| | CD13 is a therapeutic target in human liver cancer stem cells | Q30496324 |
| | High-resolution characterization of a hepatocellular carcinoma genome | Q31005512 |
| | Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial | Q33410643 |
| | Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma | Q33766930 |
| | Micro RNA expression profiles as adjunctive data to assess the risk of hepatocellular carcinoma recurrence after liver transplantation. | Q34050935 |
| | NAFLD, NASH and liver cancer | Q34374372 |
| | Biological and therapeutic impact of intratumor heterogeneity in cancer evolution | Q34457994 |
| | Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia | Q34603806 |
| | Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial | Q34663499 |
| | Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening | Q34701235 |
| | A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. | Q34721998 |
| | Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. | Q34742406 |
| | The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers | Q35958822 |
| | The changing pattern of epidemiology in hepatocellular carcinoma | Q36084797 |
| | Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets | Q36104399 |
| | Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma | Q36547263 |
| | Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma | Q36625697 |
| | Gene-expression signature of vascular invasion in hepatocellular carcinoma. | Q36759564 |
| | Integrated metabolite and gene expression profiles identify lipid biomarkers associated with progression of hepatocellular carcinoma and patient outcomes. | Q36788477 |
| | Review of the clinicopathologic features of fibrolamellar carcinoma | Q36799067 |
| | MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a | Q36924035 |
| | Targeted therapies for hepatocellular carcinoma. | Q36928888 |
| | Focal gains of VEGFA and molecular classification of hepatocellular carcinoma | Q36984575 |
| | High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions | Q37064910 |
| | Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma | Q37138658 |
| | Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma | Q37284612 |
| | Fibrolamellar carcinoma: 2012 update | Q37288706 |
| | Identification of driver genes in hepatocellular carcinoma by exome sequencing | Q37315447 |
| | A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma | Q37336698 |
| | Microvascular invasion (MVI) is a poorer prognostic predictor for small hepatocellular carcinoma | Q37580894 |
| | Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis | Q37696392 |
| | Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. | Q37760241 |
| | Liver cancer epidemic in China: past, present and future | Q37818766 |
| | Genetics of hepatobiliary carcinogenesis | Q37871482 |
| | The tumor microenvironment in hepatocellular carcinoma (review). | Q37996920 |
| | Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design | Q38192888 |
| | Pathogenesis of hepatocellular carcinoma according to aetiology | Q38254705 |
| | Hepatocellular carcinomas expressing 'stemness'-related markers: clinicopathological characteristics. | Q38265723 |
| | Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets | Q38400913 |
| | Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation | Q39003817 |
| | Liver cancer biopsy--back to the future?! | Q39120706 |
| | Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma | Q39240497 |
| | Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma | Q39290981 |
| | CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling | Q39459026 |
| | CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation | Q39512947 |
| | A seven-gene set associated with chronic hypoxia of prognostic importance in hepatocellular carcinoma | Q39686498 |
| | Tumor heterogeneity and the biology of cancer invasion and metastasis | Q39759977 |
| | Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma | Q39807521 |
| | EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma | Q40006245 |
| | Identification of local and circulating cancer stem cells in human liver cancer | Q40013131 |
| | Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma | Q40059015 |
| | Identification and characterization of tumorigenic liver cancer stem/progenitor cells | Q40119609 |
| | Trans-ancestry mutational landscape of hepatocellular carcinoma genomes | Q42182370 |
| | Intratumor heterogeneity in hepatocellular carcinoma | Q42186312 |
| | Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification | Q42220401 |
| | The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma | Q42271559 |
| | Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. | Q42978852 |
| | Specific gene-expression profiles of noncancerous liver tissue predict the risk for multicentric occurrence of hepatocellular carcinoma in hepatitis C virus-positive patients | Q43000745 |
| | Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study | Q43691230 |
| | Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma | Q44395085 |
| | Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. | Q44885846 |
| | Gene expression-based recurrence prediction of hepatitis B virus-related human hepatocellular carcinoma | Q44902374 |
| | Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning | Q45728735 |
| | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 |
| | The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma | Q46115526 |
| | Relationship of histologic grade of hepatocellular carcinoma (HCC) to tumor size, and demonstration of tumor cells of multiple different grades in single small HCC. | Q47199334 |
| | A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells | Q50115050 |
| | DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma. | Q51499838 |
| | Identification of metastasis-related microRNAs in hepatocellular carcinoma. | Q51897320 |
| | Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. | Q52087746 |
| | Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. | Q52107732 |
| | Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. | Q53232555 |
| | Liver cancer: time to evolve trial design after everolimus failure. | Q54332985 |
| | A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection | Q57756525 |
| | Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial | Q57762740 |
| | Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis | Q57972703 |
| | Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood | Q73894466 |
| | Intratumoral genomic heterogeneity in human hepatocellular carcinoma detected by restriction landmark genomic scanning | Q74034494 |
| | Tumor heterogeneity in small hepatocellular carcinoma: analysis of tumor cell proliferation, expression and mutation of p53 AND beta-catenin | Q74287340 |
| | Combined hepatocellular-cholangiocarcinoma: a histopathologic, immunohistochemical, and in situ hybridization study | Q74593923 |
| P433 | issue | 3 | |
| P304 | page(s) | 291-302 | |
| P577 | publication date | 2015-07-27 | |
| P1433 | published in | Hepatic oncology | Q27725477 |
| P1476 | title | Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice. | |
| P478 | volume | 2 | |